We showed an increased percentage of CD193+ sputum eosinophils from COPD patients compared to controls (48.1 [29.8–69.3]% vs. 18.7 [11.6–32.8]%, respectively, p = 0.028), a higher proportion of CD66b+ sputum eosinophils in COPD subjects compared to controls (67.9 [59.9–75.7]% vs. 39.1 [25.6–58.4]% and in asthma compared to controls (p = 0.024), respectively, p = 0.036), and a decreased level of CD11b+ sputum eosinophils in COPD compared to asthma (97.9 [96.6–99.1]% vs. 99.4 [98.9–100]%, respectively, p = 0.009). This evidence concerns the gene CCR3 and asthma.